Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future.
In a statment the group's Chief Executive Officer said: "We have received a number of unsolicited expressions of interest in our Injectables business and will consider the best option for shareholders."
The share price rose 4.85% to 908p by 12:05.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
American Express introduces 'Plan It' payment instalment option
News Amex users can now split parts of their credit bill into further instalments. Is it worth it?
By Marc Shoffman Published
Three fund ideas for your stocks and shares ISA
If you have yet to maximise this year’s £20,000 ISA allowance, here are some funds worth considering.
By Katie Williams Published